Animal Tester Neogen Sticks To Annual Forecast Despite Tariffs

1. NEOG reported Q1 2026 sales of $209.19 million, slightly above expectations. 2. Gross margin fell to 45.4% due to production relocations and tariffs. 3. First-quarter adjusted EBITDA was $35.5 million, lower than last year's $43.7 million. 4. Food Safety sales declined 4.6%, while Genomics showed mid-single-digit growth. 5. NEOG affirmed 2026 sales guidance of $820-$840 million, slightly above consensus.